To reduce MetS and CVD risk, cessation of AAS use is highly recommended as it has been shown to at least improve the lipoprotein profile, yet may have lasting effects on insulin sensitivity, BP and VAT levels [37, 106, 108, 163]. This evidence concerns the gene INS and metabolic syndrome.